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Isocitrate dehydrogenase 1 and 2 (IDH1 and 
IDH2) are NADP-dependent enzymes that 
catalyze the oxidative decarboxylation of isoci-
trate to -ketoglutarate (-KG) in the cyto-
plasm/peroxisome and mitochondrial matrix, 
respectively, with the concomitant production 
of  nicotinamide  adenine  dinucleotide  phos-
phate (NADPH). Their activities are distinct from 
the NAD-dependent enzyme IDH3, which func-
tions in the tricarboxylic acid cycle to produce 
the NADH required to supply the electron 
transport chain.
The  high-throughput  sequencing  of  glio-
blastoma multiforme tumors identified a novel 
mutation in IDH1 that was present in 12% of 
tumors from glioblastoma multiforme patients 
(Parsons et al., 2008). Further investigation has 
revealed that this mutation is present in a high 
proportion of gliomas and secondary glioblasto-
mas, but not in other human malignancies (Balss 
et al., 2008; Bleeker et al., 2009; Hartmann et al., 
2009; Kang et al., 2009; Sanson et al., 2009; 
Watanabe et al., 2009; Yan et al., 2009). Less 
common  mutations  in  IDH2  have  also  been 
identified in gliomas, and are mutually exclusive 
with  mutations  in  IDH1  (Hartmann  et  al.,   
2009; Sonoda et al., 2009; Yan et al., 2009). All 
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Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), are present in most gliomas and 
secondary glioblastomas, but are rare in other neoplasms. IDH1/2 mutations are heterozy-
gous, and affect a single arginine residue. Recently, IDH1 mutations were identified in 8% 
of acute myelogenous leukemia (AML) patients. A glioma study revealed that IDH1 muta-
tions cause a gain-of-function, resulting in the production and accumulation of 2-hydroxy-
glutarate (2-HG). Genotyping of 145 AML biopsies identified 11 IDH1 R132 mutant 
samples. Liquid chromatography-mass spectrometry metabolite screening revealed in-
creased 2-HG levels in IDH1 R132 mutant cells and sera, and uncovered two IDH2 R172K 
mutations. IDH1/2 mutations were associated with normal karyotypes. Recombinant IDH1 
R132C and IDH2 R172K proteins catalyze the novel nicotinamide adenine dinucleotide 
phosphate (NADPH)–dependent reduction of -ketoglutarate (-KG) to 2-HG. The IDH1 
R132C mutation commonly found in AML reduces the affinity for isocitrate, and increases 
the affinity for NADPH and -KG. This prevents the oxidative decarboxylation of isocitrate 
to -KG, and facilitates the conversion of -KG to 2-HG. IDH1/2 mutations confer an 
enzymatic gain of function that dramatically increases 2-HG in AML. This provides an 
explanation for the heterozygous acquisition of these mutations during tumorigenesis.  
2-HG is a tractable metabolic biomarker of mutant IDH1/2 enzyme activity.
© 2010 Gross et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS AND DISCUSSION
As IDH1 is a critical enzyme in cellular metabolism, the recent 
report of IDH1 mutations in AML is intriguing. To investigate 
the role of IDH1 R132 mutations in AML, we genotyped 
leukemic cells obtained at initial presentation, from a series of 
145 AML patients treated at the Princess Margaret Hospital 
with the aim of identifying mutant samples in our viable cell 
tissue bank. Heterozygous IDH1 R132 mutations were found 
in 11 (8%) of these patients (Table I). The spectrum of IDH1 
mutations in AML appears to differ from that seen in central 
nervous system (CNS) tumors. In the CNS, the majority of 
mutations (80–90%) are IDH1 R132H substitutions, whereas 
we observe 5, 4, and 2 patients with IDH1 R132H, R132C, 
and R132G mutations, respectively (Table I). This is consis-
tent with the previous report in AML (Mardis et al., 2009) and 
suggests that there may be functional differences among these 
IDH1 mutants. In four cases, leukemic cells were also available 
from samples taken at the time of relapse. The IDH1 mutation 
was retained in 4/4 of these samples (Table I). One of the 
AML patients harboring an IDH1 mutation had progressed 
from an earlier myelodysplastic syndrome (MDS). When cells 
from the prior MDS biopsy were genotyped, IDH1 was found 
to be WT. Further sequencing of a large group of well-charac-
terized MDS samples will be necessary to determine whether 
IDH1 mutations are a feature of this heterogeneous disease, 
and whether they contribute to progression to AML. In a sub-
set of IDH1 mutant patients (n = 8), reverse transcribed RNA 
was used for genotyping to assess the relative expression of 
mutant and WT alleles. Sequenom genotyping showed bal-
anced allele peaks for these samples, indicating that both the 
mutations identified to date involve a single amino acid change 
at arginine 132 (R132) of IDH1, or the analogous residue in 
IDH2 (R172). This residue is located in the active site of the 
enzyme and participates in isocitrate binding (Xu et al., 2004). 
Interestingly, all mutations are heterozygous, suggesting that 
alteration of R132 of IDH1 or R172 of IDH2 causes an enzy-
matic gain of function. Furthermore, these studies have pro-
vided evidence that the IDH1 mutation is an early event in the 
pathogenesis of the disease (Watanabe et al., 2009).
Recently, whole genome sequencing of a patient with 
acute myelogenous leukemia (AML) identified an R132 mu-
tation in IDH1 (Mardis et al., 2009). Sequencing of addi-
tional patients revealed that IDH1 is mutated at R132, mainly 
to histidine and cysteine, in 8% of AML patients, demon-
strating that this mutation is not restricted to gliomas, as pre-
viously thought (Mardis et al., 2009). More importantly, we 
recently reported that IDH1 R132 mutations confer a novel 
enzymatic activity. Surprisingly, the IDH1 R132H mutant 
protein was found to catalyze the NADPH-dependent re-
duction of -KG to 2-hydroxyglutarate (2-HG), a rare me-
tabolite normally present at very low levels in healthy cells 
and tissues (Dang et al., 2009). We set out to further investi-
gate the role of IDH mutation in AML. Our work establishes 
that IDH1 R132 mutations cause production and accumula-
tion of 2-HG in AML cells. Additionally, 2-HG screening 
uncovered previously unrecognized IDH2 mutations in AML. 
Overall, our data indicate that mutations at R132 and R172 
in the active sites of IDH1 and IDH2, respectively, lead to a 
change in the molecular mechanism of enzyme catalysis, re-
sulting in elevated levels of 2-HG in AML.
Table I.  Identification of 13 AML patients bearing an IDH1 R132 or IDH2 R172 mutation
Patient ID Mutation Amino acid 
change
FAB subtype NPM1 and FLT3 
status
Cytogenetic profile Genotype at 
relapse
2-HG level (ng/2 
× 106 cells)
IDH1 mutations
090108 G/A R132H M4 na Normal na 2,090
090356 G/A R132H na na na na 1,529
0034 C/T R132C M5a Normal Normal na 10,285
0086 C/G R132G M2 Normal Normal na 10,470
0488 C/T R132C M0 Normal Normal R132C 13,822
8587 G/A R132H na Normal Normal na 5,742
8665 C/T R132C M1 na Normal na 7,217
8741 G/A R132H M4 NPM1 Normal R132H 6,419
9544 C/G R132G na na Normal R132G 4,962
747762 G/A R132H M1 NPM1 Normal R132H 8,464
090148 C/T R132C M1 na 46, xx, i(7) (p10) [20] na na
IDH2 mutations
9382 G/A R172K M0 Normal Normal na 19,247
0831 G/A R172K M1 Normal Normal na 15,877
IDH1/2 WT
090239 WT WT na FLT3 Normal na 112
090158 WT WT M2 na 46, XX [15] na 411
090313 WT WT na na Normal na 116
FLT3, FMS-related tyrosine kinase 3 internal tandem duplications. Na indicates that some data were not available for some patients.JEM VOL. 207, February 15, 2010  341
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Unlike in glioma, where IDH1 mutant patients have 
improved outcome, there does not seem to be an effect of 
IDH1/2  mutation  status  on  most  clinical  characteristics  or 
treatment response in AML. However, the studies reported to 
date are likely not sufficiently powered to adequately address 
these questions. Further studies using larger numbers of pa-
tients will be required to determine whether IDH1 mutation 
status will be a clinically useful marker. Regardless of its effect 
on outcome, the finding that 4/4 patients retained the muta-
tion upon relapse suggests that it is stable through the course of 
disease progression, and may be clinically useful as a marker of 
minimal residual disease, as has been shown for nucleophosmin 
1 (NPM1) mutations (Schnittger et al., 2009).
To extend these findings, panels of AML cells from WT 
and IDH1 mutant patients were cultured in vitro. There was 
no difference in the growth rates or viability of the IDH1 
R132 mutant and WT cells, with both groups showing high 
variability in their ability to proliferate in culture, as is charac-
teristic of primary AML cells (Fig. S1). There was no relation-
ship between 2-HG levels in the IDH1 R132 mutant cells and 
their growth rate or viability in culture. After 14 d in culture, 
the mutant AML cells retained their IDH1 R132 mutations 
(11/11), and continued to accumulate high levels of 2-HG 
(Fig. 1 A), further confirming that IDH1 R132 mutations lead 
to the production and accumulation of 2-HG in AML cells.
To investigate the effect of IDH1/2 mutations on the 
concentration of cellular metabolites proximal to the IDH 
reaction, -KG, succinate, malate, and fumarate levels were 
measured in AML cells with IDH1/2 mutations and in a set 
of WT AML cells matched for AML subtype and cytogenetic 
profile. None of the metabolites were found to be greatly al-
tered in the IDH1 mutants compared with the IDH1 WT 
cells (Fig. 2 and Table S2). Of note, the mean level of -KG 
was not altered in the IDH1/2 mutant AML cells, suggesting 
WT and mutant genes are expressed. 10 established AML cell 
lines were also genotyped (OCI/AML-1, OCI/AML-2, OCI/
AML-3,  OCI/AML-4,  OCI/AML-5,  HL-60,  MV-4-11, 
THP-1, K562, and KG1A) and all were IDH1 WT. This find-
ing is consistent with the failure of other investigators to iden-
tify glioma or glioblastoma cell lines retaining the IDH1 R132 
mutation after long-term culture (Bleeker et al., 2009).
Because  gliomas  carrying  IDH1  mutations  accumulate 
high levels of 2-HG (Dang et al., 2009), we measured 2-HG 
in this set of AML samples. Levels of 2-HG were 50-fold 
higher in samples harboring an IDH1 R132 mutation (Table I, 
Fig. 1 A, and Table S2). 2-HG was also elevated in the sera 
of patients with IDH1 R132 mutant AML (Fig. 1 B). There 
was no relationship between the specific amino acid substitu-
tion at residue 132 and the level of 2-HG.
Interestingly, two IDH1 WT samples also showed high 
levels of 2-HG (Table I). Mutation of arginine 172 in IDH2 
has been previously reported in gliomas (Ducray et al., 2009; 
Hartmann et al., 2009; Sonoda et al., 2009; Yan et al., 2009), 
but not in AML. The high 2-HG concentration prompted 
sequencing of the IDH2 gene in these two AML samples, 
and IDH2 R172K mutations were identified in both samples 
(Table I). This is the first report of IDH2 R172K mutations 
in AML. Subsequently, all samples were screened for IDH2 
mutations, but no further mutations were identified.
Evaluation of the clinical characteristics of patients with 
or without IDH1/2 mutations revealed a significant associa-
tion between IDH1/2 mutations and normal karyotype (P = 
0.05), but no other differences (Table S1). Notably, there 
was no difference in treatment response for a subgroup of pa-
tients who received consistent treatment (n = 136). These 
findings are consistent with the initial study identifying IDH1 
mutations in AML (Mardis et al., 2009).
Figure 1.  IDH1/2 mutant AML cells and sera have increased levels 
of 2-HG. (A) Extracts from IDH1/2 WT (n = 10) and IDH1/2 mutant (n = 
16) patient leukemia cells obtained at presentation and relapse, and IDH1 
R132 mutant leukemia cells grown in culture for 14 d (n = 14) were ana-
lyzed by LC-MS to measure levels of 2-HG. (B) 2-HG was measured in sera 
of patients with IDH1 WT or IDH1 R132 mutant leukemia. In A and B, 
each point represents an individual patient sample. Diamonds represent 
WT, circles represent IDH1 mutants, and triangles represent IDH2 mutants. 
Horizontal bars indicate the mean. * indicates a statistically significant 
difference relative to WT patient cells (P < 0.05).
Figure 2.  IDH1/2 mutant AML cells do not display altered levels  
of central carbon metabolites. Extracts from leukemia cells of AML 
patients carrying an IDH1/2 mutant allele (mutant; n = 16) or WT (n = 10) 
obtained at initial presentation and relapse were assayed by LC-MS for 
levels of -KG, succinate, malate, and fumarate. Each point represents an 
individual patient sample. Open circles represent WT, closed circles repre-
sent IDH1 mutants, and triangles represent IDH2 mutants. Horizontal bars 
represent the mean. There were no statistically significant differences 
between the WT and IDH1/2 mutant AML samples.342 IDH1/2 mutations cause accumulation of 2-HG in AML | Gross et al.
R132C  protein  were  assessed  in  vitro.  Kinetic  analyses 
showed that the R132C substitution severely impairs the ox-
idative decarboxylation of isocitrate to -KG, with a signifi-
cant decrease in kcat, even though the affinity for the cofactor 
NADP+ remains essentially unchanged (Table II). However, 
unlike  the  R132H  mutant  enzyme  described  previously 
(Dang et al., 2009), the R132C mutation leads to a dramatic 
loss of affinity for isocitrate (KM), and a drop in net isocitrate 
metabolism efficiency (kcat/KM) of more than six orders of 
magnitude (Table II). This suggests a potential difference in 
the substrate-level regulation of enzyme activity in the con-
text of AML. Although substitution of cysteine at R132 in-
activates the canonical conversion of isocitrate to -KG, the 
IDH1 R132C mutant enzyme acquires the ability to catalyze 
the reduction of -KG to 2-HG in an NADPH dependent 
manner (Fig. 3 B). This reductive reaction of mutant IDH1 
R132C is highly efficient (kcat/KM) compared with the WT 
enzyme because of the considerable increase in binding affin-
ity of both the NADPH and -KG substrates (KM; Table II).
There is a group of rare, inherited, neurometabolic disor-
ders called 2-hydroxyglutaric acidurias, in which 2-HG levels 
are dramatically increased in the CNS and sera of patients 
(Rzem et al., 2007; Struys, 2006). These diseases are caused 
by homozygous loss of function mutations in the 2-HG 
that the mutation does not decrease the concentration of this 
metabolite as has been previously hypothesized (Zhao et al., 
2009). These findings are consistent with measurements made 
in glioma tissue (Dang et al., 2009), and indicate that IDH1 
mutations do not cause large changes in the cellular concen-
trations of these metabolites.
To confirm that the R132C mutation of IDH1, and the 
R172K mutation of IDH2 confer a novel enzymatic activity 
that produces 2-HG, recombinant mutant enzymes were as-
sayed for the NADPH-dependent reduction of -KG. When 
samples were analyzed by liquid chromatography mass spec-
trometry (LC-MS) upon completion of the enzyme assay, 
2-HG was identified as the end product for both the IDH1 
R132C and IDH2 R172K mutant enzymes (Fig. 3 A). No 
isocitrate was detectable by LC-MS, indicating that 2-HG is 
the sole product of this reaction (Fig. 3 A). This observation 
held true even when the reductive reaction was performed in 
buffer containing NaHCO3 saturated with CO2 (unpublished 
data), which would be expected to favor the formation of 
isocitrate via the canonical reverse reaction.
As discussed above, a large proportion of IDH1 mutant 
patients in AML have an IDH1 R132C mutation (Table I; 
Mardis et al., 2009). To biochemically characterize mutant 
IDH1  R132C,  the  enzymatic  properties  of  recombinant 
Figure 3.  Recombinant IDH1 R132C and IDH2 R172K produce 2-HG. (A) LC-MS analysis of in vitro reactions using recombinant IDH1 R132C and 
IDH2 R172K confirms that 2-HG and not isocitrate is the end product of the mutant enzyme reactions. Reactions were performed in triplicate in each 
of two independent experiments; typical chromatograms are presented. (B) The WT IDH1 enzyme catalyzes the oxidative decarboxylation of isocitrate to 
-KG, with the concomitant reduction of NADP to NADPH. The IDH1 R132C and IDH2 R172K mutants reduce -KG to 2-HG while oxidizing NADPH to 
NADP. These are referred to in the text as the “forward” and “partial reverse” reactions, respectively.JEM VOL. 207, February 15, 2010  343
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Mutations in the analogous arginine residue in the active sites 
of the two enzymes leads to the same biochemical gain of 
function. Further functional and mechanistic work will be 
required to understand the underlying biology driving the 
acquisition of these mutations, and to determine whether 
mutants of IDH1 R132 and IDH2 R172 may be useful ther-
apeutic targets.
MATERIALS AND METHODS
Patients and clinical data. Peripheral blood and bone marrow were col-
lected from AML patients at the time of diagnosis and at relapse, after in-
formed  consent  and  approval  from  the  Research  Ethics  Board  of  the 
University  Health  Network.  Sample  identification  numbers  are  unique, 
anonymous identifiers generated by the leukemia bank at the Princess Mar-
garet Hospital, and are independent of true patient ID numbers. The cells 
were separated by ficoll hypaque centrifugation, and stored at 150°C as 
described previously (Miyauchi et al., 1987). Patient sera were stored at 
80°C. Cytogenetics and molecular testing were performed in the diagnos-
tic laboratory of the University Health Network (Toronto, Canada). A sub-
group of patients (n = 132) was given consistent treatment using a standard 
induction and consolidation chemotherapy regimen consisting of daunoru-
bicin and cytarabine.
IDH1 and IDH2 genotyping. DNA was extracted from leukemic cells 
and cell lines using the Puregene kit (QIAGEN). For a subset of samples 
(n = 96), RNA was extracted using a Qiagen RNeasy kit, and reverse tran-
scribed into cDNA for genotyping. IDH1 and IDH2 genotype was deter-
mined  at  the  Analytical  Genetics  Technology  Centre  at  the  University 
Health Network using a Sequenom MassARRAY platform (Sequenom). 
Positive results were confirmed by direct sequencing.
Cell lines. AML cell lines and 5637 cells were obtained from the labora-
tory of M. Minden (Ontario Cancer Institute, Toronto, Canada). Primary 
AML cells were cultured in -MEM media with 20% fetal bovine serum 
and 10% 5637 cell-conditioned media as previously described (Miyauchi et 
al., 1987). Growth curves were generated by counting viable cells as as-
sessed by trypan blue exclusion on a Vi-CELL automated cell counter 
(Beckman Coulter).
Expression/purification  of  IDH1  and  IDH2  proteins. The human 
IDH1  cDNA  (GenBank/EMBL/DDBJ  accession  no.  NM_005896)  and 
IDH2 cDNA (GenBank/EMBL/DDBJ accession no. NM_002168) were 
purchased from OriGene Technologies. IDH1 (full length) and IDH2 (resi-
dues 40–452) were subcloned into vector pET41a (EMD Biosciences) to 
enable the E. coli expression of C-terminal His8-tagged proteins. Site- 
directed mutagenesis was performed using the QuikChange Lightning kit 
(Stratagene) to change C394 to T in IDH1 and G515 to A in IDH2, result-
ing in the R132C and R172K mutations, respectively. WT and mutant 
IDH1 proteins were expressed in and purified from the E. coli Rosetta (DE3) 
strain (Invitrogen). Overexpression of IDH2 protein was accomplished by 
co-transfection of plasmids encoding respective IDH2 clones and pG-KJE8–
expressing chaperone proteins (Nishihara et al., 1998, 2000).
IDH1/2 activity assays. Enzymatic activity was assessed by following the 
change in NADPH absorbance at 340 nm in an SFM-400 stopped-flow 
spectrophotometer (Biological) in the presence of isocitrate and NADP (for-
ward reaction) or -KG and NADPH (reverse reaction) in standard reaction 
buffer (150 mM NaCl, 20 mM Tris-Cl, pH 7.5, 10 mM MgCl2, and 0.03% 
[wt/vol] bovine serum albumin). To measure kinetic parameters, sufficient 
enzyme was added to give a linear reaction for 1–5 s. Enzymatic binding 
constants were determined using curve-fitting algorithms to standard kinetic 
models with SigmaPlot software (Systat Software). For determination of kcat, 
enzyme was incubated with 5X Km of substrate and cofactor. An extinction 
coefficient of 6,200 M1 cm1 was used for NADPH.
dehydrogenase enzymes responsible for converting 2-HG back 
into -KG. Although the phenotypes are diverse, some of 
these patients are at higher risk of developing brain tumors. 
Whether 2-HG contributes directly to tumor development is 
unknown. The existence of these diseases raises the possibility 
that mutations in genes other than IDH1 could result in an 
increase in 2-HG in tumors. 2-HG–based metabolite screening 
as performed in this study might facilitate rapid and sensitive 
identification of these mutations.
The physiological effects of elevated 2-HG are poorly 
understood. It has been reported that 2-HG can increase lev-
els of reactive oxygen species, which may drive tumor pro-
gression (Latini et al., 2003a,b). Alternatively, because of its 
high degree of structural similarity to -KG, 2-HG may bind 
and inhibit specific -KG–dependent enzymes such as the 
prolyl hydroxylases that control the stability of the hypoxia-
inducible factor transcription factors. This could explain the 
finding that hypoxia-inducible factor target genes have been 
reported to be elevated in IDH1 mutant glioma tissue (Zhao 
et al., 2009), whereas levels of -KG are not reduced in AML 
or glioma tumor cells harboring IDH1 mutations.
The surprising finding that the IDH1 R132 mutant pro-
tein acquires a novel enzymatic function provides a new ex-
planation for the heterozygous acquisition of this mutation 
during tumorigenesis (Dang et al., 2009). We have shown 
that the IDH1 R132C mutant commonly found in AML has 
the ability to reduce -KG to 2-HG in an NADPH-depen-
dent manner, and that the usually scarce -KG derivative 2-
HG is dramatically elevated in leukemia cells and sera of 
patients carrying IDH1 mutations. Our previous work has 
also shown high levels of 2-HG in glioma tissues harboring 
IDH1 R132 mutations, suggesting that this is a consistent 
feature of IDH1 R132 mutant cells and tissues (Dang et al., 
2009). In addition, we identified two IDH2 R172K muta-
tions and corresponding elevated 2-HG levels for the first 
time in AML, and showed directly that IDH2 R132K mu-
tant protein produces 2-HG in vitro. The observation that the 
mutation of IDH2 arginine 172 leads to production of 2-HG 
in AML represents an example of metabolic convergence. 
Table II.  Kinetic parameters of the IDH1 R132C mutant 
enzyme
Oxidative (→NADPH) WT R132C
KM,NADP+ (µM) 49 21
KM,isocitrate (µM) 57 8.7 × 104
KM,MgCl2 (µM) 29 4.5 × 102
Ki,KG (µM) 6.1 × 102 61
kcat (s1) 1.3 × 105 7.1 × 102
kcat /KM,isoc(M1.s1) 2.3 × 109 8.2 × 103
Reductive (→ NADP+) WT R132C
KM,NADPH (µM) na 0.3
KM,KG (µM) na 295
kcat (s1) 7 5.5 × 102
Na indicates no measureable activity.344 IDH1/2 mutations cause accumulation of 2-HG in AML | Gross et al.
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